Page 9 - Elderly Relapsed News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Elderly relapsed. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Elderly Relapsed Today - Breaking & Trending Today

Pivotal Phase 3 SIERRA Trial Data Showing 100% Bone Marrow Transplant Engraftment in Patients Treated with Iomab-B presented at the 2021 Virtual SNMMI Conference

Pivotal Phase 3 SIERRA Trial Data Showing 100% Bone Marrow Transplant Engraftment in Patients Treated with Iomab-B presented at the 2021 Virtual SNMMI Conference
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Susan Passalaqua , Hans Vitzthum , Mark Berger , Company Phase , Lifesci Advisors , Exchange Commission , Astellas Pharma Inc , Actinium Pharmaceuticals Inc , Banner Md Anderson Cancer Center , Society Of Nuclear Medicine , Memorial Sloan Kettering Cancer Center , Actinium Pharmaceuticals , Nuclear Medicine , Molecular Imaging , Annual Meeting , Chief Medical Officer , Marrow Radiation Dose , Active Relapsed , Refractory Acute Myeloid , Conventional Care , Crossed Over , Therapeutic Dose , Marrow Blast , Post Randomization , Dose Delivered , Relapse Transplant Related ,

Actinium Announces Several Presentations from the Phase 3 SIERRA Study of Iomab-B at the SNMMI 2021 Virtual Annual Meeting

/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that three abstracts highlighting data and. ....

United Kingdom , Roberto Fedrigo , Susan Passalaqua , Sandesh Seth , Hans Vitzthum , Mark Berger , Lifesci Advisors , Exchange Commission , Astellas Pharma Inc , Actinium Pharmaceuticals Inc , University Of British Columbia , Banner Md Anderson Cancer Center , Society Of Nuclear Medicine , Memorial Sloan Kettering Cancer Center , Bc Cancer Research Institute , Actinium Pharmaceuticals , Nuclear Medicine , Molecular Imaging , Chief Medical Officer , Presentation Title , Marrow Radiation Dose , Active Relapsed , Refractory Acute Myeloid , Incidence Rates , Febrile Neutropenia , Randomized Phase ,

Actinium Announces Appointment of Mark Kubik, MBA as Chief Business Officer

Actinium Announces Appointment of Mark Kubik, MBA as Chief Business Officer
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Leeds School Of Business , Sandesh Seth , Hans Vitzthum , Mark Kubik , Oncoimmune Merck , Lifesci Advisors , Pharmaceuticals Velocity Sciences , Glenmark Pharmaceuticals , Alliance Of The Year , Exchange Commission , Licensing Executives Society , Astellas Pharma Inc , University Of Colorado , Actinium Pharmaceuticals Inc , Memorial Sloan Kettering Cancer Center , Actinium Pharmaceuticals , Chief Business Officer , Protein Design Labs , Seattle Genetics , Velocity Sciences , Recombinant Capital , Life Sciences Award , Leeds School , Developmental Biology , Antibody Radiation Conjugates ,

Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies

Share this article
NEW YORK, Jan. 13, 2021 /PRNewswire/
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ( Actinium ) today announced the research collaboration with Astellas Pharma Inc. (TSE:4503) ( Astellas ) to develop novel targeted radiotherapies using its Antibody Warhead Enabling (AWE) technology platform. Under this agreement, Actinium will utilize its AWE Platform technology to develop and characterize selected Astellas targeting agents labeled with the potent alpha-emitting radioisotope Actinium-225 (Ac-225). This collaboration is a component of Astellas internal initiative to develop theranostics as part of its Rx+ ® business (For more information, please visit https://www.astellas.com/en/news/16356).
We are excited to execute on this research collaboration with Astellas, a global leader at the forefront of healthcare innovation, stated Dr. Dale Ludwig, Chief Scientific and Technology Officer of Actinium. Targeted radiotherapy has a highly di ....

United States , Dale Ludwig , Sandesh Seth , Hans Vitzthum , Clayton Robertson , Lifesci Advisors , Our Antibody Warhead Enabling Platform Technology , Technology Platform , Platform Technology , Exchange Commission , Astellas Pharma Inc , Actinium Pharmaceuticals Inc , Business Development , Actinium Pharmaceuticals , Astellas Pharma , Antibody Warhead Enabling , Chief Scientific , Technology Officer , Chief Executive Officer , Patient Journey , Antibody Radiation Conjugates , Bone Marrow Transplant , Gene Therapy , Adoptive Cell Therapy , Elderly Relapsed , Refractory Acute Myeloid Leukemia ,